Implementing improved analytical methods to support vaccine quality - Part 1 (from Sep 15)

Thursday, September 24, 2020 5:30 PM to 7:40 PM · 2 hr. 10 min. (Africa/Abidjan)
Pre-congress workshops
Vaccine Showcases

Information

Watch on demand on Sep 24, or join LIVE on Sep 15 by registering here:

www.attendee.gotowebinar.com/register/6511056480271037965

Sep 15: PART ONE: approx. 10AM EST – 12PM EST

Workshop opening remarks

Dr Earl Zablackis, Director-Principle Scientist, Sanofi Pasteur

Molecular size, from distribution coefficient to multiple measured characteristics using light scattering-not as easy as you would think

Dr Earl Zablackis, Director-Principle Scientist, Sanofi Pasteur

Use of NMR assays for characterization of polysaccharide-based vaccines 

Francesco Berti, Scientific Director – Analytical/Technical R&D, GSK Vaccines 

Substituting in vitro for in vivo vaccine potency and safety assays: science versus the fear factor: Dr Dean Smith, Section Head & Senior Scientific Evaluator of Vaccines, Health Canada

A regulatory perspective on NGS for adventitious virus detection in biologics 

Dr Arifa Khan, Principal Investigator/Supervisory Microbiologist in the Division of Viral Products, CBER, FDA 


Panel with all speakers 

Moderated by Dr Dirk Redlich, VP, Head CMC Development and Clinical Trial Material Manufacturing, Janssen